• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

作者信息

Huggins C, Hodges C V

出版信息

CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40. doi: 10.3322/canjclin.22.4.232.

DOI:10.3322/canjclin.22.4.232
PMID:4625049
Abstract
摘要

相似文献

1
Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.前列腺癌研究。I. 去势、雌激素及雄激素注射对前列腺转移性癌血清磷酸酶的影响。
CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40. doi: 10.3322/canjclin.22.4.232.
2
Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.前列腺癌研究。I. 去势、雌激素及雄激素注射对前列腺转移性癌血清磷酸酶的影响。1941年。
J Urol. 2002 Feb;167(2 Pt 2):948-51; discussion 952.
3
Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V. Hodges.前列腺癌研究I. 阉割、雌激素及雄激素注射对前列腺转移性癌血清磷酸酶的影响，作者查尔斯·哈金斯和克拉伦斯·V·霍奇斯
J Sex Med. 2010 Feb;7(2 Pt 1):640-4. doi: 10.1111/j.1743-6109.2009.01680.x.
4
Hypophysectomy for reactivated disseminated prostatic carcinoma.
S Afr Med J. 1972 Sep 9;46(36):1278-85.
5
PROGNOSTICATION OF CARCINOMA OF THE PROSTATE METASTATIC TO THE SKELETON BY RADIOLOGICAL STUDIES.通过放射学研究对前列腺癌骨转移进行预后评估
J Urol. 1964 Dec;92:714-20. doi: 10.1016/S0022-5347(17)64039-4.
6
[Prostatic cancer: indications for hormone therapy].[前列腺癌：激素治疗的指征]
MMW Munch Med Wochenschr. 1979 Mar 2;121(9):300-2.
7
THE TREATMENT OF METASTATIC PROSTATIC CANCER WITH DITHIZONE (DIPHENYLTHIOCARBAZONE).
Invest Urol. 1963 Nov;1:229-37.
8
[POSSIBILITIES OF "GUIDED" ENDOCRINE-SURGICAL TREATMENT IN CANCER OF THE PROSTATE].[前列腺癌“引导式”内分泌手术治疗的可能性]
Arch Ital Urol. 1964 Apr;36:423-40.
9
Bilateral adrenalectomy for advanced prostatic carcinoma.双侧肾上腺切除术治疗晚期前列腺癌。
J Urol. 1972 Jul;108(1):123-5. doi: 10.1016/s0022-5347(17)60659-1.
10
Cyproterone acetate in the treatment of advanced carcinoma of the prostate.醋酸环丙孕酮治疗晚期前列腺癌
J Urol. 1973 Jul;110(1):106-8. doi: 10.1016/s0022-5347(17)60128-9.

引用本文的文献

1
Synthesis and Computational Evaluation of ‑Acetyl-Derived Schiff Bases Incorporating 1,2,4-Triazoles for Dual Inhibition of Prostate Cancer Cells and Carbonic Anhydrases.含1,2,4-三唑的α-乙酰基衍生席夫碱对前列腺癌细胞和碳酸酐酶双重抑制作用的合成与计算评估
ACS Omega. 2025 Aug 22;10(34):38585-38608. doi: 10.1021/acsomega.5c03271. eCollection 2025 Sep 2.
2
ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by regulating glycolysis.新型雄激素受体靶点ECD通过调节糖酵解促进前列腺癌肿瘤发生。
Oncogene. 2025 Sep 4. doi: 10.1038/s41388-025-03559-x.
3
Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study.
初发性激素敏感性转移性前列腺癌患者的患者及医生特征与雄激素剥夺治疗强化的关联：一项基于人群的研究
Cancer. 2025 Sep 15;131(18):e70070. doi: 10.1002/cncr.70070.
4
Tuning probe permeability chalcogen and halogen atom substitution for monitoring alkaline phosphatase activity in mammalian cells.通过调整探针渗透性、硫族元素和卤素原子取代来监测哺乳动物细胞中的碱性磷酸酶活性。
Chem Sci. 2025 Aug 19. doi: 10.1039/d5sc04585a.
5
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer.SOX2利用FOXA1作为异源转录伙伴来驱动去势抵抗性前列腺癌的增殖。
bioRxiv. 2025 Jul 19:2025.07.18.664790. doi: 10.1101/2025.07.18.664790.
6
Neuregulin-1 correlates to early castration-resistant prostate cancer after prostate cancer patients receiving androgen deprivation therapy.在前列腺癌患者接受雄激素剥夺治疗后，神经调节蛋白-1与早期去势抵抗性前列腺癌相关。
J Cancer. 2025 Jul 11;16(10):3261-3269. doi: 10.7150/jca.112954. eCollection 2025.
7
PRMT5:MEP50 Are Mediators of Treatment-Induced Neuroendocrine Differentiation in Prostate Cancer.PRMT5:MEP50是前列腺癌治疗诱导神经内分泌分化的介质。
Prostate. 2025 Jul 17. doi: 10.1002/pros.70006.
8
Phenotypic Plasticity and Androgen Receptor Bypass Drive Cross-Resistance to Apalutamide in Castration-Resistant Prostate Cancer Cell Models.表型可塑性和雄激素受体旁路驱动去势抵抗性前列腺癌细胞模型对阿帕鲁胺的交叉耐药
Int J Mol Sci. 2025 Jun 20;26(13):5939. doi: 10.3390/ijms26135939.
9
Recent advances in drug treatment for prostate cancer.前列腺癌药物治疗的最新进展。
Jpn J Radiol. 2025 Jun 18. doi: 10.1007/s11604-025-01816-3.
10
Optimizing Radiation Therapy for Localized Prostate Cancer: Exploring Synergies With Androgen Deprivation Therapy and Novel Systemic Agents.优化局限性前列腺癌的放射治疗：探索与雄激素剥夺疗法及新型全身治疗药物的协同作用
Semin Radiat Oncol. 2025 Jul;35(3):474-487. doi: 10.1016/j.semradonc.2025.04.001.